Business

Mass. Movers

ArQule slides again after study disappoints

Associated Press/File 2012

Advertisement

Shares of ArQule Inc. of ­Woburn continued to slide after the company on Friday said a study showed the combined use of its lead drug candidate with two other cancer-fighting treatments did not meet survival targets for patients with a certain type of colorectal cancer. ArQule is engaged in the development of next-generation, small-molecule cancer therapeutics. Its products and research programs focus on key biological processes that are central to human cancers.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.